NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1 The price hikes were more than twice the rate of…
Transbronchial Lung Cryobiopsy a Valid Diagnostic Option in Interstitial Lung Disease
NEW YORK (Reuters Health)—Transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB) had a high level of agreement for diagnosing interstitial lung disease in the first comparative study. “These data suggest that TBLC, when done by an experienced proceduralist, is a valid first-line minimally invasive diagnostic tool for patients with interstitial lung disease deemed to…
More Than Skin Deep: Insights into Clinical Challenges in Psoriatic Arthritis
Accurately classifying patients with psoriatic arthritis (PsA) can be difficult, especially patients with monoarticular/oligoarticular and polyarticular forms of PsA. A session at the 2019 European Congress of Rheumatology provided insight into the assessment and treatment of PsA subtypes…
Lupus Flares Pose Greatest Risk for Adverse Pregnancy Outcomes in Women with SLE
According to new research, women with SLE are at the highest risk for adverse pregnancy outcomes during a lupus flare. The data may enable clinicians to use risk stratification and tailored monitoring to counsel SLE patients who are pregnant or considering pregnancy. Researchers also found that maternal age, lupus nephritis and antiphospholipid antibodies may affect pregnancy outcomes…
Annual Meeting Preview: Effective Advocacy By & For ACR/ARP Members
Session attendees will hear about recent successes from the Government Affairs Committee and learn how to become effective rheumatology advocates.
Practice & Society Donations Advance Advocacy Efforts for Rheumatologists & Patients
A new RheumPAC fund, which supports awareness and operations of the ACR’s political action committee, has exceeded an initial goal of $20,000 by two times in its first year.
Innovative Education Formats & More: What’s New at the 2019 ACR/ARP Annual Meeting
With innovative session formats and unique spaces that encourage learning and networking, the 2019 ACR/ARP Annual Meeting will offer exciting new opportunities for rheumatology professionals. Here’s a sneak peek…
Sit Back & Enjoy Learning at the 2019 ACR/ARP Annual Meeting
With innovative session formats and unique spaces that encourage networking, the 2019 ACR/ARP Annual Meeting will offer new and exciting opportunities for rheumatology professionals. Here’s a sneak peek…
Gut Instinct: Ankylosing Spondylitis & the Microbiome
CHICAGO—At the 2019 ACR State-of-the-Art Clinical Symposium, an annual gathering featuring talks by key opinion leaders on the most salient topics for practicing rheumatologists and healthcare providers, Jose U. Scher, MD, director of the Microbiome Center for Rheumatology and Autoimmunity at NYU Langone Medical Center, New York City, was the featured speaker. In his remarks,…
Nintedanib Slows Lung Deterioration in General Fibrosing Interstitial Lung Disease
NEW YORK (Reuters Health)—Nintedanib dramatically slows lung deterioration in patients with progressive fibrosing interstitial lung diseases, according to a new randomized study.1 Nintedanib has already been shown to be effective against idiopathic pulmonary fibrosis (IPF). The new trial, funded by the manufacturer, Boehringer Ingelheim, and presented t the European Respiratory Society International Congress 2019 in…
- « Previous Page
- 1
- …
- 238
- 239
- 240
- 241
- 242
- …
- 815
- Next Page »